Cargando…
Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives
SIMPLE SUMMARY: Ovarian cancer (OC) represents the fifth leading cause of cancer-related deaths among women. In the advanced disease setting, OC recurrence after chemotherapy is over 70% in the first 2 years, with few therapeutic options. Immunotherapy with the immune checkpoint inhibitors (ICIs) sh...
Autores principales: | Maiorano, Brigida Anna, Maiorano, Mauro Francesco Pio, Lorusso, Domenica, Maiello, Evaristo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430975/ https://www.ncbi.nlm.nih.gov/pubmed/34503248 http://dx.doi.org/10.3390/cancers13174438 |
Ejemplares similares
-
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022) -
Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023) -
The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022) -
How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
por: Maiorano, Brigida Anna, et al.
Publicado: (2022) -
Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)